Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients
Figure 6
Lymphocyte activation responses in patients and controls.
a: Responses towards antigens and mitogens in healthy controls and patients before and after one year of natalizumab treatment. For visualization purposes, data are normalized to the average of the healthy controls for the respective antigens. Analysis performed with one-way ANOVA with Tukey´s post hoc test. * p<0.05, comparison between controls and pre-treatment patients. ¶ p<0.05, comparison between pre- and post-treatment patients. n=23 for controls, n=37 for both pre- and post-treatment groups. Bars show mean values, whiskers denote SEM. b-c: Fraction of activated lymphocytes in response to influenza (b) and CMV (c). Groups compared with Kruskall-Wallis test, utilizing Dunn´s post-hoc test. Median and interquartile range are shown. * p<0.05, ** p<0.01, *** p<0.005.